Engineers Gate Manager LP Purchases 101,699 Shares of Vera Therapeutics, Inc. $VERA

Engineers Gate Manager LP increased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 1,579.2% during the second quarter, Holdings Channel reports. The fund owned 108,139 shares of the company’s stock after purchasing an additional 101,699 shares during the period. Engineers Gate Manager LP’s holdings in Vera Therapeutics were worth $4,640,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of VERA. California State Teachers Retirement System lifted its holdings in Vera Therapeutics by 4,071.9% during the 2nd quarter. California State Teachers Retirement System now owns 2,074,999 shares of the company’s stock worth $89,038,000 after buying an additional 2,025,262 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after buying an additional 1,795,537 shares during the period. Vestal Point Capital LP boosted its holdings in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after buying an additional 600,000 shares during the last quarter. Elmind Capital LP bought a new position in Vera Therapeutics during the 4th quarter worth approximately $24,434,000. Finally, Armistice Capital LLC grew its holdings in shares of Vera Therapeutics by 294.1% in the 3rd quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock valued at $15,576,000 after buying an additional 400,000 shares during the period. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Stock Up 4.3%

Shares of NASDAQ VERA opened at $35.05 on Friday. The stock has a 50-day moving average price of $35.11 and a two-hundred day moving average price of $37.18. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -5.98 and a beta of 0.96. Vera Therapeutics, Inc. has a 12 month low of $22.72 and a 12 month high of $56.05. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter last year, the business posted ($1.20) earnings per share. As a group, analysts forecast that Vera Therapeutics, Inc. will post -6.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $35.12, for a total transaction of $649,720.00. Following the sale, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $8,261,769.28. The trade was a 7.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 83,250 shares of company stock worth $3,307,800. 15.90% of the stock is owned by company insiders.

Analyst Ratings Changes

VERA has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Bank of America boosted their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a research note on Wednesday, July 8th. Guggenheim boosted their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $80.15.

Vera Therapeutics Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.